🟢 Teva Pharma is trading 5% up today after Q3 earnings beat and outlook raise

Teva Pharma is trading at $42.65 (+4.79%) after third-quarter adjusted EPS of $0.86 and $4.4 billion revenue beat analyst expectations.

• Management raised its 2026 revenue outlook to $16.7–$17.0 billion and increased forecasts for AUSTEDO, AJOVY, and UZEDY.
• Those three innovative brands grew 33%, offsetting weaker generic sales.
• Non-GAAP gross margin reached a decade high.